Cord Blood Microtransplantation for Treatment of Acute Myeloid Leukemia

The Affiliated Hospital of the Chinese Academy of Military Medical Sciences20 enrolled

Overview

Discuss the effectiveness and safety of cord blood microtransplantation for treatment of acute myeloid leukemia

The investigators conducted a prospective, single center clinical trial to dissuss the outcomes and toxicities of HLA-mismatched cord blood infusion after chemotherapy (microtransplantation) in older patients with acute myeloid leukemia (AML)

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Safety Issues Efficiency

Interventions

microtransplantationBIOLOGICAL

HLA mismatched donor cord blood infusion

Eligibility

Sex: ALLMin age: 60 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. de novo acute myeloid leukemia 2. age 60-80 Exclusion Criteria: 1. have no suitable donor or donor refused 2. patient refused to accept donor cells

Locations (1)

The First Affiliated Hospital of USTC

Hefei, China

RECRUITING

Outcomes

Primary Outcomes

complete remission rate

Bone marrow \<5% blasts； Absolute neutrophil count \>1000/mcL； Platelets ≥100,000/mcL；No residual evidence of extramedullary disease.

Time frame: 1 month

time of hematopoietic recovery

Absolute neutrophil count \>500/mcL; Platelets ≥20,000/mcL

Time frame: 1 month

Secondary Outcomes

time to progression

Measured from complete remission to the relapse

Time frame: 2 year

Central Contacts

Wen Yao

CONTACT

055162283730 yaowen0511@163.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.